Basis of Presentation (Details) In Millions, except Share data, unless otherwise specified					0 Months Ended
	Mar. 31, 2014 USD ($)	Feb. 28, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 28, 2013 Healthtronics [Member] USD ($)	Feb. 28, 2014 Paladin Labs Inc. [Member] USD ($)	Feb. 28, 2014 Paladin Labs Inc. [Member] CAD	Feb. 03, 2014 Boca Pharmacal, LLC [Member] USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash payment issued per share of acquired entity (cd per share)					$ 1.09	1.16
Number of New Endo shares Issued per share of Paladin Labs (shares)					1.6331	1.6331
Number of New Endo shares issued per share of Endo (shares)					1	1
Common Stock, shares authorized			350,000,000
Common Stock, par value		$ 0.01	$ 0.01
Ordinary Shares, shares authorized	1,000,000,000
Ordinary Shares, par value	$ 0.0001
Euro Deferred Shares, shares issued	4,000,000
Euro Deferred Shares, par value	$ 0.01
Upfront cash payment subject to cash and other working capital adjustments				$ 85.0
Future cash payments based on operating performance				45.0
Approved plan consideration amount				130.0
Payments to acquire business							$ 232.7